基于登记的日本蛛网膜下腔出血研究:高发病率及近期基于生活方式的下降趋势
该研究利用日本厚生劳动省与日本神经外科学会登记数据,估算2003至2015年全国年龄标准化蛛网膜下腔出血(SAH)发病率从31.34例/10万人年降至27.63例/10万人年(下降11.8%),粗发病率从23.79降至20.25例/10万人年(下降14.9%)。同期高血压患病率和当前吸烟率显著下降,降胆固醇药物使用显著增加,生活方式改善可能促成SAH发病率下降。
要点
- 2003至2015年日本估算年龄标准化SAH发病率显著下降,从31.34降至27.63例/10万人年(下降11.8%)。
- 估算粗SAH发病率从23.79降至20.25例/10万人年(下降14.9%),趋势显著。
- 未破裂脑动脉瘤治疗数量显著增加(p<0.0001),但估算治疗率仅0.19至0.51。
核心结论
- 日本估算的全国SAH发病率高于其他国家,但近期已下降,生活方式改善可能促成该下降。
研究设计与样本
- 基于登记的全国性研究,数据来自日本厚生劳动省和日本神经外科学会记录,估算2003至2015年年龄标准化SAH发病率、粗发病率及未破裂脑动脉瘤治疗率,并评估相关生活方式因素趋势。
主要发现
- 估算年龄标准化SAH发病率从31.34例(95%CI 31.32-31.34)降至27.63例(95%CI 27.59-27.63)/10万人年,下降11.8%。
- 估算粗SAH发病率从23.79例(95%CI 23.78-23.79)降至20.25例(95%CI 20.24-20.25)/10万人年,下降14.9%。
- 敏感性分析中估算年龄标准化SAH发病率变化率范围为-56.69%至23.27%,均值-30.91%(SD 20.52%),92%的趋势呈下降。
- 2003至2015年未破裂脑动脉瘤治疗数量显著增加(p<0.0001),但估算治疗率仅0.19(95%CI 0.19-0.20)至0.51(95%CI 0.50-0.51)。
- 高血压患病率(男性p=0.0003;女性p<0.0001)和当前吸烟率(男性p<0.0001;女性p=0.0002)显著下降,降胆固醇药物使用显著增加(男性p<0.0001;女性p=0.0005)。
关键数值与推荐
- 估算年龄标准化SAH发病率下降基于2010年人口参考,并假设SAH病死率从2003年44%每年下降1%至2015年32%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Japan has been reported to have the highest (and increasing) incidence of subarachnoid hemorrhage (SAH) in the world. However, there has never been a report on the nationwide incidence rate and recent trends for SAH in Japan. In this register-based study, the authors aimed to clarify the estimated nationwide SAH incidence rate and the recent trend in SAH incidence in Japan and the reasons for any changes in this trend. METHODS: The authors compiled data from the Japanese Ministry of Health, Labour and Welfare and from the records of the Japan Neurosurgical Society. They reviewed the age-standardized nationwide SAH mortality rate, the estimated age-standardized SAH incidence rate according to the age-standardized SAH mortality rate, and the estimated crude SAH incidence rate, including the 95% confidence intervals, from 2003 to 2015. The trends in the number of treatments for unruptured and ruptured cerebral aneurysms, as well as the prevalence of hypertension, current smoking status, and use of cholesterol-lowering drugs, were assessed. The estimated treatment rate for unruptured cerebral aneurysms (UCAs) was also calculated along with the 95% confidence interval. RESULTS: The estimated age-standardized nationwide SAH incidence rate significantly declined from 31.34 cases (95% CI 31.32-31.34) to 27.63 (95% CI 27.59-27.63; decrease by 11.8%) per 100,000 person-years. This decline was based on the 2010 population as the reference from 2003 through 2015 and a case-fatality rate of SAH that was assumed to decrease by 1% annually from 44% in 2003 to 32% in 2015. According to sensitivity analysis, the change rate of the estimated age-standardized SAH incidence rate ranged from -56.69% to 23.27%, with a mean of -30.91% (SD 20.52%), and there were decline trends in 92% of all trends. The estimated nationwide crude SAH incidence rate also showed a significant decline from 23.79 (95% CI 23.78-23.79) to 20.25 (95% CI 20.24-20.25; decrease by 14.9%) per 100,000 person-years. The trend in treatment numbers for UCAs increased significantly (p < 0.0001) from 2003 through 2015; however, the estimated treatment rate for UCAs was only 0.19 (95% CI 0.19-0.20) to 0.51 (95% CI 0.50-0.51) among all UCA patients. The prevalence of hypertension (males, p = 0.0003; females, p < 0.0001) and current smoking status (males, p < 0.0001; females, p = 0.0002) declined significantly from 2003 through 2015, while the use of cholesterol-lowering drugs increased significantly (males, p < 0.0001; females, p = 0.0005) during the same period. CONCLUSIONS: The estimated nationwide SAH incidence rate in Japan was higher than rates in other countries, although it has declined recently. An improving lifestyle may have contributed to the declining rate of SAH incidence in Japan.
引用
- Ikawa F, Morita A, Nakayama T, et al. A register-based SAH study in Japan: high incidence rate and recent decline trend based on lifestyle. J Neurosurg. 2020. PMID: 32217794. doi:10.3171/2020.1.JNS192848
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。